Jerusalem-based biopharmaceutical firm Gamida Cell Ltd. is at the forefront of developing cell therapies to cure blood cancers and serious blood diseases. With its lead product candidate, omidubicel, the company recently completed Phase III clinical trials for patients with hematologic malignancies and is also testing it in Phase II clinical trials for severe aplastic anemia. Additionally, Gamida is working on GDA-201, an investigational NK cell-based cancer immunotherapy that is currently in Phase I/II studies targeting relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998, the clinical-stage company is making strides to combat life-threatening diseases and revolutionize the biopharmaceutical industry.
Gamida Cell Ltd.'s ticker is GMDA
The company's shares trade on the NASDAQ stock exchange
They are based in Boston, Massachusetts
There are 51-200 employees working at Gamida Cell Ltd.
It is https://www.gamida-cell.com/
Gamida Cell Ltd. is in the Healthcare sector
Gamida Cell Ltd. is in the Biotechnology industry
The following five companies are Gamida Cell Ltd.'s industry peers: